A four-week randomized study in healthy older adults measured pulsatile growth-hormone release and IGF-1 during oral MK-677 exposure. A later two-year randomized trial examined hormone measures, body composition and clinical outcomes in healthy adults aged 60 to 81. The longer trial reported changes in growth-hormone, IGF-1 and fat-free mass but did not show improvement in strength or physical function.
That last point matters. A biomarker or body-composition change is not automatically a meaningful functional benefit. The studies involved selected research participants, structured follow-up and a defined investigational product. They do not establish what every compounded preparation will do, and they do not support calling ibutamoren an anti-aging treatment.
Ghrelin biology also reaches beyond growth-hormone release. The receptor participates in appetite and energy-balance signaling, so increased appetite can be relevant rather than incidental. Growth-hormone and IGF-1 signaling can influence fluid balance and glucose regulation as well. Those connections are mechanisms to monitor, not benefits to advertise.
The longer trial is especially useful because it separates intermediate measures from daily function. Researchers could observe changes in hormone levels and fat-free mass while strength and physical function did not improve. That gap is a reminder that laboratory and body-composition endpoints should not be translated into claims about energy, recovery, muscle performance or independence.
